Evidence map›Paper›PMID 31456335›Full record

ArticleInternational journal of clinical practice2019

Impact of nocturia on patients' health-related quality of life and healthcare resource utilisation compared with OAB and BPH: Results from an observational survey in European and American patients.

Veronica Y Zeng, Gary Milligan, James Piercy, Peter Anderson, Fredrik L Andersson

Open access · bronzeAbstract read
In one paragraph

Article in International journal of clinical practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Psychometric validation and interpretation of the Nocturia Impact Diary in a clinical trial setting.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Trial
  2. Article
  3. Article
  4. Psychometric evaluation of the Nocturia Sleep Quality Scale based on data from a prospective observational study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2021
    Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Veronica Y ZengFerring Pharmaceuticals A/S, Copenhagen, Denmark.
Gary MilliganAdelphi Real World, Bollington, Cheshire, UK.
James PiercyAdelphi Real World, Bollington, Cheshire, UK.
Peter AndersonAdelphi Real World, Bollington, Cheshire, UK.
Fredrik L AnderssonFerring Pharmaceuticals A/S, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-6304-5781
Adelphi Group (United Kingdom) · GBFerring Pharmaceuticals (Denmark) · DKLinköping University · SE

Funding

Ferring Pharmaceuticals A/S
6 · The paper itself

Abstract

objectiveTo evaluate the impact of nocturia on patients' quality of life and healthcare resource utilisation (HRU) compared with overactive bladder (OAB) and benign prostatic hyperplasia (BPH).

methodsData were drawn from a multinational (France, Germany, Spain, UK and US) survey of physician and patient-reported outcomes. The patient groups of interests were those diagnosed with only nocturia, with only OAB, and with only BPH. Health-related quality of life (HRQoL) and productivity measures were derived from the EuroQoL-5D, OAB-q and the Work Productivity and Activity Impairment Questionnaire (WPAI). Measures of HRU included lower urinary tract symptoms (LUTS)-relevant surgeries, hospitalisations, current use of pads and related physician visits. Bivariate and multivariate regression analyses were used to evaluate associations between HRQoL/HRU/Productivity and nocturia status. Multivariate analysis was used to address any potential confounding factors among the groups, ie age, gender, body mass index (BMI), ethnicity and comorbidities.

resultsA total of 3552 patients were identified including 358 nocturia patients, 1415 OAB patients and 1779 BPH patients. The mean age of the nocturia patients was 61.2 years with a mean BMI of 27.3. About 60.6% were women, 87.2% were Caucasian, and their most common comorbidities included depression, hypertension and diabetes. In terms of impact, nocturia patients were significantly worse off than OAB patients in their HRQoL. There was no significant difference regarding HRU and productivity measurement. Nocturia patients also presented with significantly worse HRQoL and lower productivity compared with BPH patients. Nocturia patients also had more physician visits.

conclusionsNocturia should be emphasised as a standalone LUTS disease with substantial patient impact. Compared with OAB and/or BPH, nocturia patients presented with a significant reduction on patients' quality of life, reduced work productivity and increased utilisation of healthcare resources.

Indexed as

benign prostatic hyperplasiahealthcare resource utilisation (HRU)health-related quality of lifeimpactnocturiaoveractive bladderproductivity

Identifiers

PMID31456335
PMCPMC9285556
OpenAlexW2971088750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.